This research lab is now in an FDA-approved clinical trial using convention-enhanced delivery (CED), or interstitial infusion, a method whose early development was funded in part through IFF research. As the study progresses, new patients will be treated with increasing doses as Dr. Mark Souweidane monitors the effectiveness of each dosage. The study has included 13 patients over the last two years, with a requested extension now pending with the FDA. The team at Weill Cornell is happy to report that no adverse effects have occurred at any dose.
For more information, visit: